Cerenovus
Cerenovus, a wholly-owned subsidiary of Johnson & Johnson MedTech, manufactures neurointerventional medical devices, including the CereGlide aspiration catheter family and the Cerepak detachable coil systems, for use by hospitals and stroke treatment centers in acute ischemic stroke and intracranial aneurysm procedures.
- Company typePrivate
- Founded2009
- HeadquartersIrvine, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cerenovus does
Cerenovus is a United States-based neurointerventional medical device manufacturer operating as a wholly-owned subsidiary of Johnson & Johnson MedTech, the medical technology division of Johnson & Johnson (NYSE: JNJ). Headquartered in Irvine, California, the company focuses on devices for acute ischemic stroke intervention and intracranial aneurysm embolization, sold to hospitals and specialized stroke treatment centers through J&J MedTech's enterprise field-sales and hospital procurement channels. Pricing is quote-based and not publicly disclosed, consistent with hospital medical device contracting.
The product portfolio comprises two families. The CereGlide aspiration catheter family, launched in the U.S. in February 2026, consists of the CereGlide 42 and CereGlide 57 aspiration catheters plus the InnerGlide 7 delivery aid; devices feature proprietary variable-stiffness construction, hydrophilic coatings to reduce friction during navigation, and TruCourse technology intended to improve trackability to distal clots in ischemic stroke procedures. The Cerepak detachable coil family (Uniform, Heliform, and Freeform variants) targets intracranial aneurysm embolization and is currently subject to a voluntary Class I recall following higher-than-expected failure-to-detach rates linked to one death and four serious injuries, with no estimated market availability date provided by the company.
The business model is hardware sales to acute care hospitals and neurointerventional centers under procurement contracts, leveraging J&J MedTech's global commercial organization across North America, EMEA, Asia Pacific, and Latin America. The company employs 501-1,000 people, holds four registered trademarks (CereGlide, Cerepak, InnerGlide, TruCourse), and relies on physician education, peer networks, and industry conferences as mid-funnel marketing channels under the J&J MedTech umbrella.
Cerenovus firmographics
Firmographics- Name
- Cerenovus
- Legal name
- CERENOVUS Inc.
- Website
- https://jnjmedicaldevices.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Cerenovus, a wholly-owned subsidiary of Johnson & Johnson MedTech, manufactures neurointerventional medical devices, including the CereGlide aspiration catheter family and the Cerepak detachable coil systems, for use by hospitals and stroke treatment centers in acute ischemic stroke and intracranial aneurysm procedures.
- Ownership category
- akta.pro rank
Cerenovus industry classification
Industry- Product category
- Neurointerventional Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
- akta.pro secondary industries
- Stroke & Vascular Neurology (HLAKAIAG), Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)
Keywords
Where Cerenovus is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Markets served
Cerenovus business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Aspiration Catheter Sales: Sale of CereGlide aspiration catheters (CereGlide 42, CereGlide 57) and InnerGlide 7 delivery aid for stroke treatment procedures in hospitals and neurointerventional centers
- Detachable Coil Systems: Sale of Cerepak detachable coil systems (Uniform, Heliform, Freeform) for intracranial aneurysm embolization. Currently subject to Class I recall with no estimated availability date.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Cerenovus product offering
Product offeringCore offering
Cerenovus manufactures neurointerventional medical devices for the treatment of acute ischemic stroke and intracranial aneurysms. Its product portfolio centers on aspiration catheters (CereGlide 42 and CereGlide 57) with a delivery aid (InnerGlide 7) for clot removal, and detachable coil systems (Cerepak Uniform, Heliform, and Freeform) for aneurysm embolization. Devices are sold to hospitals and specialized stroke centers through J&J MedTech's commercial organization.
Product overview
Cerenovus, a unit of Johnson & Johnson MedTech, manufactures neurointerventional medical devices for stroke treatment and intracranial aneurysm procedures. The product portfolio consists of two main device families: the CereGlide aspiration catheter family (CereGlide 42, CereGlide 57, and InnerGlide 7 delivery aid) designed for aspiration-first stroke intervention, and the Cerepak detachable coil systems (Uniform, Heliform, and Freeform variants) designed for embolization of intracranial aneurysms. The CereGlide devices feature proprietary variable-stiffness construction, hydrophilic coating, and TruCourse technology for enhanced trackability and clot removal in ischemic stroke cases.
Differentiator
Problem solved
Functional benefit
Products and services
- CereGlide 42 Aspiration Catheter Aspiration catheter for neurointerventional procedures designed to reach and remove clots in ischemic stroke cases; features proprietary variable-stiffness construction, hydrophilic coating for reduced friction, and TruCourse technology for enhanced trackability.
- CereGlide 57 Aspiration Catheter Aspiration catheter for neurointerventional procedures designed to reach and remove distal clots in ischemic stroke cases; features proprietary variable-stiffness construction, hydrophilic coating for reduced friction, and TruCourse technology for enhanced trackability.
- InnerGlide 7 Delivery Aid Delivery aid designed to simplify procedural decisions and enhance performance across device sizes within J&J MedTech's aspiration-first stroke portfolio during neurointerventional workflows.
- Cerepak Uniform Detachable Coil System Detachable coil system designed for embolization of intracranial aneurysms; affected by Class I recall following reports of death and serious injuries linked to higher-than-expected failure to detach rates that can cause hemorrhagic and ischemic strokes.
- Cerepak Heliform Detachable Coil System Detachable coil system designed for embolization of intracranial aneurysms; affected by Class I recall due to higher-than-expected failure to detach rates.
- Cerepak Freeform Detachable Coil System Detachable coil system designed for embolization of intracranial aneurysms; affected by Class I recall due to higher-than-expected failure to detach rates.
Quantifiable outcome
- CereGlide catheters feature proprietary variable-stiffness construction, hydrophilic coating, and TruCourse technology for trackability
Companies that use Cerenovus
Customer profileSegments1 record
Ideal customer profiles1 record
Cerenovus technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Cerenovus partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Johnson & Johnson MedTechflagshipCerenovus is a subsidiary and integral part of Johnson & Johnson MedTech. J&J MedTech announced the launch of CereGlide aspiration catheters in the U.S. market, completing the CereGlide family for its aspiration-first stroke portfolio. The devices were developed within J&J MedTech's neurointerventional business unit to simplify procedural decisions and enhance performance across device sizes in neurointerventional workflows.
Scale indicators2 records
Recent moves4 records
Expansion highlights4 records
Cerenovus competitors and assessment
Company assessmentEmerging players
- Rapid Medical: Rapid Medical develops innovative neurovascular devices including the Tigertriever stent retriever and adjustable aneurysm devices, representing an emerging competitor in the same stroke intervention and aneurysm treatment markets as Cerenovus.
- Phenox GmbH: Phenox is a European-based neurovascular company specializing in flow diverters and stent retrievers for aneurysm and stroke treatment, representing a focused emerging competitor in Cerenovus's core markets.
Direct peers
- MicroPort Scientific Corporation: MicroPort's neurovascular business offers aspiration catheters and flow diverter devices for stroke and aneurysm treatment, competing directly with Cerenovus in the neurointerventional device market.
- Penumbra, Inc. Penumbra is a direct competitor in the neurovascular space, with a leading aspiration thrombectomy platform (Penumbra System, RED reperfusion catheters) that competes head-to-head with Cerenovus's CereGlide family in acute ischemic stroke.
- Stryker (Neurovascular): Stryker's Neurovascular division offers stent retrievers (Trevo), aspiration catheters, and detachable coils for aneurysm embolization, directly overlapping with both Cerenovus's CereGlide aspiration line and the recalled Cerepak coil portfolio.
- Medtronic (Neurovascular): Medtronic's Neurovascular business competes across both ischemic stroke intervention (stent retrievers, aspiration catheters) and aneurysm embolization (detachable coils), making it a broad-based competitor to Cerenovus's neurovascular portfolio.
Broad incumbents
- Terumo (Neurovascular): Terumo's neurovascular division offers access catheters and guidewires used in stroke intervention, providing complementary and competing products to Cerenovus's aspiration catheter and delivery aid portfolio.
- Integra LifeSciences: Integra LifeSciences has a broader neurosurgery and neurocritical care portfolio with adjacent neurovascular offerings, competing in the same hospital and neurosurgeon call point as Cerenovus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights5 records
Customer concentration
Cerenovus social profiles
Digital presenceCerenovus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cerenovus leadership team
Management profileNumber of profiles
Profiles1 record
Cerenovus funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cerenovus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cerenovus
What does Cerenovus do?
Cerenovus manufactures neurointerventional medical devices for the treatment of acute ischemic stroke and intracranial aneurysms. Its product portfolio centers on aspiration catheters (CereGlide 42 and CereGlide 57) with a delivery aid (InnerGlide 7) for clot removal, and detachable coil systems (Cerepak Uniform, Heliform, and Freeform) for aneurysm embolization. Devices are sold to hospitals and specialized stroke centers through J&J MedTech's commercial organization.
Is Cerenovus a public or private company?
Cerenovus is a private company. It is classified as corporate owned and is currently operating.
When was Cerenovus founded?
Cerenovus was founded in 2009. It employs 501 to 1,000 people.
Where is Cerenovus based?
Cerenovus is headquartered in Irvine, United States, in the North America region.
How does Cerenovus make money?
Two revenue lines are on record. Aspiration Catheter Sales are the primary driver. The others are detachable Coil Systems.
Who are Cerenovus's main competitors?
Emerging players on record are Rapid Medical and Phenox GmbH. Direct peers are MicroPort Scientific Corporation, Penumbra, Inc., Stryker (Neurovascular) and Medtronic (Neurovascular). Broad incumbents are Terumo (Neurovascular) and Integra LifeSciences.
Does Cerenovus have an API?
No public API is recorded for Cerenovus.
What industry is Cerenovus in?
Cerenovus's product category is Neurointerventional Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices, with a secondary code of HLAKAIAG, Stroke & Vascular Neurology. Its NAICS code is 339112 and its SIC code is 3841.